The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Multiple myeloma epidemiology and survival: A unique malignancy
Open accessAbstract
Multiple myeloma (MM), although a rare disease, is the second most common hematologic malignancy. It is found in the spectrum of plasma cell dyscrasias which begins with monoclonal gammopathy of unknown significance to overt plasma cell leukemia and extramedullary myeloma. MM is associated with significant morbidity due to its end-organ destruction. It is a disease of the older population and its incidence in the African American population is twice that of the European American population. Improvements in the treatment of MM in the past couple of decades, beginning with the use of autologous stem cell transplantation followed by availability of novel treatments such as immunomodulatory drugs and proteasome inhibitors has transformed the natural history of the disease leading to longer survival times. Advancements in the diagnosis, monitoring, and treatment of MM are of the utmost importance as the general population lives longer due to other improvements in health care. The recent introduction of novel therapies has been paralleled by advancements in the monitoring of MM, namely, by the availability exquisitely sensitive techniques in detecting minimal residual disease. As drug development and technology continues to improve, it will be important to design rationale clinical trials enrolling patient populations which represent the overall population including racial minorities and the elderly so trial results can be appropriately extrapolated. This manuscript reviews the changing epidemiology, the improvements in survival, and the health disparity observed in important subgroups of MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Prevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Sant, M., Allemani, C., Tereanu, C., De Angelis, R., Capocaccia, R., Visser, O., Marcos-Gragera, R., Maynadié, M., Simonetti, A., Lutz, J.-M., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282632 · Cited by 977
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Kyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Blade, J., Merlini, G., Kröger, N., Einsele, H., Vesole, D. H., Dimopoulos, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.60 · Cited by 888
A monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J., Verma, P., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 569
Kim, J. H., Kim, J. W., Kim, Y. N., Kim, H. I., Kim, J. Y., Kwon, G. Y., Kim, K., & Jang, H. R. (2015) · Case Reports in Nephrology and Dialysis · doi:10.1159/000439267 · Cited by 538
Recent major improvement in long-term survival of younger patients with multiple myeloma
Brenner, H., Gondos, A., & Pulte, D. (2008) · Blood · doi:10.1182/blood-2007-08-104984 · Cited by 535
Kyle, R. A., & Greipp, P. R. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006123022405 · Cited by 452
Racial disparities in incidence and outcome in multiple myeloma: a population-based study
Waxman, A. J., Mink, P. J., Devesa, S. S., Anderson, W. F., Weiss, B. M., Kristinsson, S. Y., McGlynn, K. A., & Landgren, O. (2010) · Blood · doi:10.1182/blood-2010-07-298760 · Cited by 411
Kristinsson, S. Y., Landgren, O., Dickman, P. W., Derolf, Å. R., & Björkholm, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0100 · Cited by 319
Rajkumar, S. V., Landgren, O., & Mateos, M.-V. (2015) · Blood · doi:10.1182/blood-2014-09-568899 · Cited by 269
Landgren, O., Graubard, B. I., Katzmann, J. A., Kyle, R. A., Ahmadizadeh, I., Clark, R., Kumar, S. K., Dispenzieri, A., Greenberg, A. J., Therneau, T. M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.34 · Cited by 208
Turesson, I., Velez, R., Kristinsson, S. Y., & Landgren, O. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4177 · Cited by 195
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., & Melton, L. J. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.859 · Cited by 194
Improved long-term survival in multiple myeloma up to the age of 80 years
Kristinsson, S. Y., Anderson, W. F., & Landgren, O. (2014) · Leukemia · doi:10.1038/leu.2014.23 · Cited by 151
Phekoo, K. J., Schey, S., Richards, M. A., Bevan, D. H., Bell, S., Gillett, D., & Møller, H. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05207.x · Cited by 151
Multiple Myeloma in Patients Younger Than 30 Years: Report of 10 Cases and Review of the Literature
Bladé, J. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440120125014 · Cited by 121
Modernizing Eligibility Criteria for Molecularly Driven Trials
Kim, E. S., Bernstein, D. S., Hilsenbeck, S. G., Chung, C. H., Dicker, A. P., Ersek, J. L., Stein, S., Khuri, F. R., Burgess, E. F., Hunt, K. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1854 · Cited by 115
Familial Multiple Myeloma: a Family Study and Review of the Literature
Lynch, H. T., Sanger, W. G., Pirruccello, S. J., Quinn‐Laquer, B., & Weisenburger, D. D. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.19.1479 · Cited by 103
Landgren, O. (2013) · Hematology · doi:10.1182/asheducation-2013.1.478 · Cited by 100
Schaapveld, M., Visser, O. J., Siesling, S., Schaar, C. G., Zweegman, S., & Vellenga, E. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.07.006 · Cited by 83
Baker, A., Braggio, E., Jacobus, S., Jung, S., Larson, D., Therneau, T., Dispenzieri, A., Van Wier, S. A., Ahmann, G., Levy, J., et al. (2013) · Blood · doi:10.1182/blood-2012-07-443606 · Cited by 66
Costa, L. J., Hari, P. N., & Kumar, S. K. (2016) · Leukemia & Lymphoma · doi:10.3109/10428194.2016.1170828 · Cited by 57
Ruzafa, J. C., Merinopoulou, E., Baggaley, R. F., Leighton, P., Werther, W., Felici, D., & Cox, A. P. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3927 · Cited by 49
Early mortality in multiple myeloma
Costa, L. J., Gonsalves, W. I., & Kumar, S. K. (2015) · Leukemia · doi:10.1038/leu.2015.33 · Cited by 39
Kazandjian, D. G., Mailankody, S., Korde, N., & Landgren, O. (2014) · PubMed · Cited by 23
Self-citationWeiss, B. M. (2013) · Blood · doi:10.1182/blood-2013-03-487215 · Cited by 9
Jian, Y., & Chen, W.-M. (2014) · 白血病·淋巴瘤 · doi:10.3760/cma.j.issn.1009-9921.2014.05.001 · Cited by 8
The Road to Treating Smoldering Multiple Myeloma
Korde, N., Mailankody, S., & Landgren, O. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.04.012 · Cited by 5
Cited by
Moreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00592-4 · Cited by 392
Huang, J., Chan, S. C., Lok, V., Zhang, L., Lucero-Prisno, D. E., Xu, W., Zheng, Z.-J., Elcarte, E., Withers, M., & Wong, M. C. S. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00165-x · Cited by 229
Deep representation learning of electronic health records to unlock patient stratification at scale
Landi, I., Glicksberg, B. S., Lee, H.-C., Cherng, S., Landi, G., Danieletto, M., Dudley, J. T., Furlanello, C., & Miotto, R. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0301-z · Cited by 213
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Martin, T. G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., Wiederschain, D., et al. (2019) · Cells · doi:10.3390/cells8121522 · Cited by 166
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Metadata
- Authors
- Kazandjian, D.
- Venue
- Seminars in Oncology
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 43
- Issue
- 6
- Pages
- 676-681
- ISSN
- 0093-7754 (ISSN-L)
- OpenAlex
- W2549396793
- Cited by
- 765
- References
- 42
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.